[{"Assets_0_Q3_USD":609772000.0,"CommonStockSharesOutstanding_0_Q3_shares":295700576.0,"EarningsPerShareBasic_1_Q3_USD":0.28,"EarningsPerShareBasic_3_Q3_USD":0.39,"EarningsPerShareDiluted_1_Q3_USD":0.26,"EarningsPerShareDiluted_3_Q3_USD":0.37,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":112258000.0,"NetIncomeLoss_1_Q3_USD":81382000.0,"NetIncomeLoss_3_Q3_USD":115738000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":312940000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":311555000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":294269000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":292776000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20171101"}]